LOG IN
SIGN UP
MARKET
ABUS
ABUS
Arbutus Biopharm
NASDAQ
2.720
+0.150
+5.84%
Closed 18:44 12/08 EST
OPEN
2.580
PREV CLOSE
2.570
HIGH
2.745
LOW
2.557
VOLUME
737.86K
TURNOVER
--
52 WEEK HIGH
4.670
52 WEEK LOW
1.850
MARKET CAP
425.59M
P/E (TTM)
-5.6432
1D
5D
1M
3M
1Y
5Y
Companies Like Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 1d ago
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
Benzinga · 3d ago
Arbutus Biopharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Arbutus Biopharma ( NASDAQ:ABUS ) Third Quarter 2022 Results Key Financial Results Revenue: US$5.95m (up 78% from 3Q...
Simply Wall St. · 11/11 10:20
HC Wainwright & Co. Maintains Buy on Arbutus Biopharma, Lowers Price Target to $6
Benzinga · 11/10 11:27
--HC Wainwright Adjusts Price Target on Arbutus Biopharma to $6 From $7.50, Maintains Buy Rating
--HC Wainwright Adjusts Price Target on Arbutus Biopharma to $6 From $7.50, Maintains Buy Rating
MT Newswires · 11/10 09:55
Arbutus trades higher as Q3 net loss narrows, revenue grows on license deal
Seekingalpha · 11/09 17:26
BRIEF-Arbutus Reports Q3 Financial Results, Provides Corporate Update
Reuters · 11/09 14:55
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 46.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/09 13:45
About ABUS
Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The Company is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).
Webull offers kinds of Arbutus Biopharma Corp stock information, including NASDAQ:ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.